Antonio Asensi Cantó

Dr. Antonio Asensi Cantó

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ACAntonio Asensi Cantó
Antonio Asensi Cantó
MAMaría Dolores López Abellán
María Dolores López Abellán
VCVerónica Castillo-Guardiola
Verónica Castillo-Guardiola
AHAna María Hurtado
Ana María Hurtado
MMMónica Martínez-Penella
Mónica Martínez-Penella
PCPablo Conesa-Zamora
Pablo Conesa-Zamora
Growing evidence shows that nerves play an active role in cancer development and progression by altering crucial molecular pathways and cell functions. Conversely, the use of neurotropic drugs, such as tricyclic antidepressants (TCAs), may modulate these molecular signals with a therapeutic purpose based on a direct antitumoral effect and beyond the TCA use to treat neuropathic pain in oncology patients. In this review, we discuss the TCAs’ safety and their central effects against neuropathic pain in cancer, and the antitumoral effects of TCAs in in vitro and preclinical studies, as well as in the clinical setting. The current evidence points out that TCAs are safe and beneficial to treat neuropathic pain associated with cancer and chemotherapy, and they block different molecular pathways used by cancer cells from different locations for tumor growth and promotion. Likewise, ongoing clinical trials evaluating the antineoplastic effects of TCAs are discussed. TCAs are very biologically active compounds, and their repurposing as antitumoral drugs is a promising and straightforward approach to treat specific cancer subtypes and to further define their molecular targets, as well as an interesting starting point to design analogues with increased antitumoral activity.